vismodegib   Click here for help

GtoPdb Ligand ID: 6975

Synonyms: Erivedge® | GDC-0449 | HhAntag691
Approved drug PDB Ligand
vismodegib is an approved drug (FDA (2012), EMA (2013))
Compound class: Synthetic organic
Comment: Vismodegib inhibits smoothened homolog (SMO), a constituent of the Hedgehog signalling pathway which is essential for proper embryonic development. This pathway is also involved in the maintenance and regeneration of adult tissues by regulating adult stem cells and has been implicated in the development of some cancers.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 84.51
Molecular weight 420.01
XLogP 4.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1ccc(cc1Cl)S(=O)(=O)C)Nc1ccc(c(c1)c1ccccn1)Cl
Isomeric SMILES O=C(c1ccc(cc1Cl)S(=O)(=O)C)Nc1ccc(c(c1)c1ccccn1)Cl
InChI InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
InChI Key BPQMGSKTAYIVFO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Vismodegib is approved for the treatment of basal-cell carcinoma.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of SMO prevents activation of the transcription factors GLI1 and GLI2, and tumor mediating genes within the hedgehog pathway are prevented from being expressed.
External links Click here for help